Ultragenyx Pharmaceutical Inc RARE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
40.90UNCH (UNCH)
Volume
14,125
Close
40.90quote price arrow down-0.32 (-0.78%)
Volume
535,517
52 week range
31.52 - 54.98
Loading...
  • Open41.54
  • Day High41.56
  • Day Low40.26
  • Prev Close41.22
  • 52 Week High54.98
  • 52 Week High Date06/06/23
  • 52 Week Low31.52
  • 52 Week Low Date10/24/23

Key Stats

  • Market Cap3.40B
  • Shares Out83.13M
  • 10 Day Average Volume0.85M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change-14.47

KEY STATS

  • Open41.54
  • Day High41.56
  • Day Low40.26
  • Prev Close41.22
  • 52 Week High54.98
  • 52 Week High Date06/06/23
  • 52 Week Low31.52
  • 52 Week Low Date10/24/23
  • Market Cap3.40B
  • Shares Out83.13M
  • 10 Day Average Volume0.85M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change-14.47

RATIOS/PROFITABILITY

  • EPS (TTM)-8.02
  • P/E (TTM)-5.10
  • Fwd P/E (NTM)-6.36
  • EBITDA (TTM)-550.835M
  • ROE (TTM)-340.05%
  • Revenue (TTM)442.586M
  • Gross Margin (TTM)88.59%
  • Net Margin (TTM)-138.58%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ultragenyx Pharmaceutical Inc

Profile

MORE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab)...
Daniel Welch
Independent Chairman of the Board
Emil Kakkis M.D., Ph.D.
President, Chief Executive Officer, Director
Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Dennis Huang
Executive Vice President, Chief Technical Operations Officer and Gene Therapy Operations
Eric Crombez M.D.
Executive Vice President, Chief Medical Officer
Address
60 Leveroni Ct
Novato, CA
94949-5746
United States

Top Peers

SYMBOLLASTCHG%CHG
FOLD
Amicus Therapeutics Inc
9.23-0.25-2.64%
INSM
Insmed Inc
25.97-0.41-1.55%
AXSM
Axsome Therapeutics Inc
72.50-1.18-1.60%
TXG
10X Genomics Inc
25.99-0.40-1.52%
IMCR
Immunocore Holdings PLC
58.95-0.90-1.50%